T2	Pharmacological_substance 34 77	recombinant tissue factor pathway inhibitor
T3	Disorder 82 95	severe sepsis
N1 	Reference T3 UMLS:C0243026	severe sepsis
T5	Disorder 242 248	sepsis
N2 	Reference T5 UMLS:C0243026	sepsis
T15	Pharmacological_substance 452 461	tifacogin
N1000 	Reference T15 MeSH:C400709	tifacogin
T16	Disorder 525 538	severe sepsis
N3 	Reference T16 UMLS:C0243026	severe sepsis
T17	Disorder 623 636	severe sepsis
N4 	Reference T17 UMLS:C0243026	severe sepsis
T20	Disorder 966 979	severe sepsis
N5 	Reference T20 UMLS:C0243026	severe sepsis
T22	Pharmacological_substance 1059 1068	tifacogin
N1001 	Reference T22 MeSH:C400709	tifacogin
T27	Pharmacological_substance 1253 1262	tifacogin
N1002 	Reference T27 MeSH:C400709	tifacogin
T35	Pharmacological_substance 1758 1767	Tifacogin
N1003 	Reference T35 MeSH:C400709	Tifacogin
T45	Disorder 2159 2167	bleeding
N6 	Reference T45 UMLS:C0019080	bleeding
T50	Pharmacological_substance 2315 2324	tifacogin
N1004 	Reference T50 MeSH:C400709	tifacogin
T51	Disorder 2379 2392	severe sepsis
N7 	Reference T51 UMLS:C0243026	severe sepsis
T52	Pharmacological_substance 2407 2416	Tifacogin
N1005 	Reference T52 MeSH:C400709	Tifacogin
T53	Disorder 2475 2483	bleeding
N8 	Reference T53 UMLS:C0019080	bleeding
T21	Pharmacological_substance 463 479	recombinant TFPI
T25	Pharmacological_substance 1117 1124	placebo
N1006 	Reference T25 MeSH:D010919	placebo
T23	Subject 1165 1177	201 patients
T24	Subject 930 943	1754 patients
T29	Pharmacological_substance 1266 1273	placebo
N1007 	Reference T29 MeSH:D010919	placebo
T30	Subject 1641 1653	722 patients
T31	Pharmacological_substance 2213 2222	tifacogin
N1008 	Reference T31 MeSH:C400709	tifacogin
T32	Pharmacological_substance 2232 2239	placebo
N1009 	Reference T32 MeSH:D010919	placebo
T34	Pharmacological_substance 2259 2268	tifacogin
N1010 	Reference T34 MeSH:C400709	tifacogin
T40	Pharmacological_substance 2278 2285	placebo
N1011 	Reference T40 MeSH:D010919	placebo
T42	Pharmacological_substance 1955 1964	tifacogin
N1012 	Reference T42 MeSH:C400709	tifacogin
T44	Pharmacological_substance 2175 2184	tifacogin
N1013 	Reference T44 MeSH:C400709	tifacogin
T46	Pharmacological_substance 2016 2023	placebo
N1014 	Reference T46 MeSH:D010919	placebo
T48	Pharmacological_substance 1697 1704	placebo
N1015 	Reference T48 MeSH:D010919	placebo
T49	Pharmacological_substance 1718 1727	tifacogin
N1016 	Reference T49 MeSH:C400709	tifacogin
T54	Pharmacological_substance 1339 1348	tifacogin
N1017 	Reference T54 MeSH:C400709	tifacogin
T55	Pharmacological_substance 1587 1595	tifacogi
N1018 	Reference T55 MeSH:C400709	tifacogi
T56	Pharmacological_substance 1600 1607	placebo
N1019 	Reference T56 MeSH:D010919	placebo
T57	Subject 2365 2373	patients
T61	Subject 648 656	patients
T63	Pharmacological_substance 23 32	tifacogin
N1020 	Reference T63 MeSH:C400709	tifacogin
T1	Subject 228 236	patients
T6	Subject 511 519	patients
T8	Pharmacological_substance 699 706	placebo
N1021 	Reference T8 MeSH:D010919	placebo
T18	Disorder 662 669	low INR
T7	Speculation_cue 2467 2471	risk
T9	Speculation_cue 421 430	determine
T11	Disorder 543 582	elevated international normalized ratio
T12	Speculation_cue 596 602	assess
T13	Pharmacological_substance 603 612	tifacogin
N1022 	Reference T13 MeSH:C400709	tifacogin
T19	Disorder 986 994	high INR
T33	Disorder 2397 2405	high INR
T37	Negation_cue 2329 2331	no
T38	Disorder 2352 2361	mortality
N9 	Reference T38 UMLS:C0020494	mortality
